Search research articles
Contact Us
Filters
Showing results (131-140 of 234) with videos related to
Page
of 24
Sort By:
Eclinicalmedicine
|
October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
Ken Herrmann, Andrei Gafita, Johann S de Bono, et al.
European Urology
|
March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
Karim Fizazi, Kim N Chi, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 14, 2023
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study
Axel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, et al.
Cancer Discovery
|
January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
European Urology Oncology
|
December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
Eric J Small, Kim N Chi, Simon Chowdhury, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
The Journal of Urology
|
July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial
Soumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists
Sebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Gillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2022
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Kim N Chi, Alan Barnicle, Caroline Sibilla, et al.
Page
of 24
Search research articles
Search
Showing results (131-140 of 234) with videos related to
Sort By:
Page
of 24
Eclinicalmedicine
|
October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
Ken Herrmann, Andrei Gafita, Johann S de Bono, et al.
European Urology
|
March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
Karim Fizazi, Kim N Chi, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 14, 2023
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study
Axel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, et al.
Cancer Discovery
|
January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
European Urology Oncology
|
December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
Eric J Small, Kim N Chi, Simon Chowdhury, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
The Journal of Urology
|
July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial
Soumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists
Sebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Gillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2022
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Kim N Chi, Alan Barnicle, Caroline Sibilla, et al.
Page
of 24